Announcement on Subsidiary Receiving Upfront Payment for Cooperation, Option, and License Agreement with AstraZeneca

CSPC Innovation Pharmaceutical Co., Ltd.·August 12, 2026·2 pages

✨ AI Summary

This announcement details that CStone Pharmaceuticals' subsidiary, Giant Biologics, received a $30 million upfront payment from AstraZeneca for a strategic collaboration on novel RNAi therapeutics. The agreement focuses on developing and commercializing new liver-targeted siRNA drugs. This payment signifies the smooth progress of the partnership and supports the company's strategic pipeline development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300765

Securities Abbreviation: CStone Pharma

Announcement Number: 2026-072

CStone Pharmaceuticals Co., Ltd.

Announcement on Subsidiary Receiving Upfront Payment for Cooperation, Option, and License Agreement with AstraZeneca

The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.

CStone Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company")'s holding subsidiary, Giant Biologics Pharmaceutical Co., Ltd. (hereinafter referred to as "Giant Biologics"), received an upfront payment of US$30 million from AstraZeneca on August 12, 2026 (the actual amount received will be net of bank fees). The specific details are hereby announced as follows:

I. Agreement Signing

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.